Krause Kevin Michael has filed 12 insider transactions across 1 company since February 2023.
Most recent transaction: a grant/award of 30000 shares of AN2 Therapeutics, Inc. ($ANTX) on March 15, 2024.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | A | Common Stock | 30000 | $0.00 | 31,914.0000 | 23,600,107 | 1567.40% | 0.13% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 23,600,107 | 9999.99% | 0.25% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | A | Common Stock | 30000 | $0.00 | 31,914.0000 | 23,600,107 | 1567.40% | 0.13% |
| Jan. 9, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | S | Common Stock | 7417 | $20.14 | 1,914.0000 | 23,600,107 | 79.49% | 0.03% |
| Jan. 9, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | M | Stock Option (right to buy) | 2417 | $0.00 | 49,868.0000 | 23,600,107 | 4.62% | 0.01% |
| Jan. 9, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | M | Stock Option (right to buy) | 5000 | $0.00 | 26,832.0000 | 23,600,107 | 15.71% | 0.02% |
| Jan. 9, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | M | Common Stock | 2417 | $0.42 | 4,331.0000 | 23,600,107 | 126.28% | 0.01% |
| Jan. 9, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | M | Common Stock | 5000 | $6.60 | 9,331.0000 | 23,600,107 | 115.45% | 0.02% |
| Jan. 2, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | M | Stock Option (right to buy) | 2583 | $0.00 | 52,285.0000 | 23,600,107 | 4.71% | 0.01% |
| Jan. 2, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | M | Common Stock | 2583 | $0.42 | 4,497.0000 | 23,600,107 | 134.95% | 0.01% |
| Jan. 2, 2024 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | S | Common Stock | 2583 | $20.12 | 1,914.0000 | 23,600,107 | 57.44% | 0.01% |
| Feb. 15, 2023 | AN2 Therapeutics, Inc. | $ANTX | Krause Kevin Michael | Chief Strategy Officer | A | Stock Option (right to buy) | 62200 | $0.00 | 62,200.0000 | 0 | 9999.99% | 0.00% |